Publication date: Jun 19, 2024
For the past three years, the pandemic has had a major effect on global public health, mainly on those with underlying medical conditions, such as people living with Multiple Sclerosis. Vaccination among this group is of great importance, and the long-term impacts of vaccination and its safety on the health of these patients will continue to be revealed. Therefore, risks related to vaccination and immune response need to be assessed. The objective here was to characterize the immune response, short-term safety, and the effects of multiple variables on these factors after COVID-19 vaccination (mainly Sinopharm) among people with Multiple Sclerosis. We assessed the short-term safety and humoral SARS-COV-2 anti-RBD IgG response using a data collection form and Immunoassay, respectively. No severe adverse events or MS relapse was observed. Myalgia/body pain (26. 7%), low-grade fever (22. 2%), and mild headache (15. 6%) were the most common adverse events. The use and type of vaccine influenced the frequency of side effects with a p-value